Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10381 in Advanced Solid Tumors
NCT05378178Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10381 in solid tumor (advanced stage), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
HS-10381
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05378178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378178.